Çocuklarda infkuenza infeksiyonları

Çocuklarda influenza klinik semptomları, ani başlangıçtı ateş, baş ağrısı, yaygın miyalji, kırgınlık ve daha sonra gelişen solunum sistemi semptomları ile karakterizedir. influenza virusu dışında da bazı viruslar ile influenza benzeri hastalık tablosu gelişebilir. Sağlıklı çocuklarda influenza atak hızı genellikle % 15-42 arasında değişir. 2 yaş altındaki küçük çocuklarda hastaneye yatış hızı klasik olarak risk grubu olarak kabul edilen 50-64 yaş erişkinlerden daha yüksektir. Tanıda genellikle viral kültür ve hızlı viral antijen testleri kullanılır. Tedavide amantadin, rimantadin, oseltamivir, zanamivir (inhalasyon), profllakside ise. amantadin, rimantadin, oseltamivir önerilir. Ancak profllakside tercih edilen yol aşılamadır. Özellikle risk grupları ve 6-24 ay sağlıklı çocuklara ve onların ev içi temaslılarına yıllık influenza aşılaması tavsiye edilmesi uygundur.

Anahtar Kelimeler:

İnfluenza, insan, Kimyasal önleme, Tanı, Epidemiyolojik faktörler, Aşılama, Çocuk

Influenza infections in children

The clinical symptoms of influenza infection in children are characterized by sudden onset of fever, headache, diffuse myalgia, and malaise with subsequent respiratory tract symptoms. Influenza like illness is caused by certain viruses other than the influenza virus. The annual rate of influenza is usually between 15-42 % in healthy children. The risk ofhospitalization in young children under two years is higher than the classical risk group of 50-64 years old adults. Diagnostic tests usually consist of viral culture or rapid diagnostic antigen tests. Amantadin, rimantadin, oseltamivir and zanamivir (inhalation) are recommended for treatment and amantadin, rimantadin and oseltamivir for prophylaxis. However the preferred method of prophylaxis is vaccination. Annual influenza immunization should be encouraged especially in risk groups and healthy children 6-24 months of age and their household contacts.

Keywords:

Influenza, Human, Chemoprevention, Diagnosis, Epidemiologic Factors, Vaccination, Child,

PDF

___

1. American Academy of Pediatrics: Influenza, “Pickering LK (ed): Red Book: 2003 Report of the Committee on Infectious Diseases, 26 baskı, s.382-91,AmericanAcademy of Pediatrics, Elk GroveVillage, IL(2003).
2. American Academy of Pediatrics Committee on Infectious Diseases: Reduction of the influenza burden in children, Pediatrics 2002;110 (6): 1246-52.
3. American Academy of Pediatrics Committee on Infectious Diseases: Recommendations for influenza immunization of children, Pediatrics 2004;113(5):1441-7.
4. Belshe RB, Gruber WC, Mendelman PM et al: Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sidney) not contained in the vaccine, J Pediatr 2000;136(2):168-75.
5. Belshe RB, Gruber WC, Mendelman PM et al: Correlates of immune protection induced by live attenuated, cold-adapted, trivalent intranasal influenza virus vaccine, J Infect Dis 2000;181(3):1133-7.
6. Belshe RB,Mendelman PM,Teanor J et al: The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children, N Engl J Med 1998;338(20):1405-12.
7. Burroughs M,Horga MA,Murrel MT,MosconaA: Respiratory infections, “GershonAA, Hotes PJ, Katz SL (eds): “Krugman’s Infectious Diseases of Children. 11. baskı” kitabında s.493-529, Mosby Co, St Louis (2004).
8. Can Çalışkan S, Çelebi S, Hacımustafaoğlu M: Bursa’da influenza virus enfeksiyonlarının değerlendirilmesi, 4. Ulusal Çocuk Enfeksiyon Hastalıkları Kongresi, Özet kitabı s.277, P-67, İstanbul (2005).
9. Çocuk Enfeksiyon Hastalıkları Derneği: Çocuklarda Üst Solunum Yolu Enfeksiyonları Çalışma Grubu Raporu, s. 1-17. Çocuk Enfeksiyon Hastalıkları Derneği Yayınları, İstanbul (2002).
10. Glezen WP: Serious morbidity and mortality associated with influenza epidemics, Epidemiol Rev 1982;4:25-44.
11. Glezen WP, Couch RB: Interpandemic influenza in the Houston area, 1974-76, N Engl J Med 1978;298(11):587-92.
12. GlezenWP, Decker M, Joseph SW,Mercready RG Jr:Acute respiratory disease associated with influenza epidemics in Houston, 1981-1983,J Infect Dis 1987;155(6):1119-26.
13. Hoberman A, Greenberg DP, Paradise JL et al: Efficacy of inactivated influenza vaccine in preventing acut otitits media in young children: a randomized controlled trial, JAMA 2003;290(12):1608-16.
14. Luce BR, Zangwill KM, Palmer CS et al: Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children, Pediatrics 2001;108(2):e24 [URL: http://www. pediatrics. org/cgi/content/full/108/2/e24].
15. Meissner HC:Antiviral drugs for prophylaxis and treatment of influenza, Pediatr Infect Dis J 2001;20(12):1165-7.
16. NeuzilKM,DupontWD,Wright PF, Edwards KM: Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985-1990: The pediatric experience, Pediatr Infect Dis J 2001;20(8):733-40.
17. Neuzil KM, Mellen BG,Wright PF,Mitchel EF, GriffinMR: The effect of influenza on hospitalizations, outpatient visits, and courses of intibiotics in children, N Engl J Med 2000;342(4):225-31.
18. Neuzil KM, ZhuY, Griffin MR et al: Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study, J Infect Dis 2002;185(2):147-52.
19. Piedra PA, Yan L, Kotloff K et al: Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children, Pediatrics 2002;110(4): 662-72.
20. Quach C, Piche-Walker L, Platt R, Moore D: Risk factors associated with severe influenza infections in childhood. Implication for vaccine strategy, Pediatrics 2003;112:e197-201.
21. Zangwill KM, Belshe RB: Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination, Pediatr Infect Dis J 2004;23(3):189-97.
22. Zangwill KM, Droge J, Mendelman P et al: Prospective, randomized, plasebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children, Pediatr Infect Dis J 2001;20(8):740-6.